Please use this identifier to cite or link to this item:
|Title:||Haemodynamic effects of ketanserin following coronary artery bypass grafting||Authors:||Lee, E.J.E.
|Issue Date:||1991||Citation:||Lee, E.J.E., Lee, T.L., Woo, M., Boey, W.K., Kumar, A., Lee, C.N. (1991). Haemodynamic effects of ketanserin following coronary artery bypass grafting. Anaesthesia and Intensive Care 19 (3) : 351-356. ScholarBank@NUS Repository.||Abstract:||The haemodynamic effects of ketanserin were studied consecutively in seventeen patients in the intensive care unit following coronary artery bypass grafting. Hypertensive patients (Group I, systolic blood pressure (SBP) ≥ 150 mmHg following discontinuation of nitroprusside, n = 10) received intravenous ketanserin 10 mg and infusion of 0.1 mg·kg-1·hr-1 with additional boluses as required to maintain SBP ≤ 130 mmHg for one hour. Non-hypertensive patients (Group 2, SBP < 150 mmHg, n = 7) received a 5 mg bolus and the same infusion. Ketanserin significantly decreased arterial blood pressure (P < 0.001) in all patients in Group 1. Heart rate was decreased but not significantly. Cardiac index, systemic and pulmonary vascular resistance and pulmonary shunt fraction were not significantly altered from pre-ketanserin values when blood pressure was controlled with nitroprusside. Normotensive patients in Group 2 did not show any undesitable hypotension or significant haemodynamic changes. Mean nitroprusside dose requirements following ketanserin therapy were significantly reduced by 91.6% in Group 1 and 78.4% in Group 2 (P < 0.05). Ketanserin is effective in treating hypertension following coronary artery bypass grafting with an advantage of lack of reflex tachycardia.||Source Title:||Anaesthesia and Intensive Care||URI:||http://scholarbank.nus.edu.sg/handle/10635/132500||ISSN:||0310057X|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on May 22, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.